MPM Oncology Impact Management »

Taysha Gene Therapies shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Taysha Gene Therapies (TSHA) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Taysha Gene Therapies

Tip: Access up to 7 years of quarterly data

All positions including Taysha Gene Therapies held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Taysha Gene Therapies by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $31M 4.5M 6.81
2025-06-30 $6.8M 3.0M 2.31

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics 230031106 (CGEM)
Aktis Oncology 01021M104 (AKTS)
Liquidia Corporation 53635D202 (LQDA)
Revolution Medicines 76155X100 (RVMD)
Corcept Therapeutics 218352102 (CORT)
Edgewise Therapeutics 28036F105 (EWTX)
Travere Therapeutics 89422G107 (TVTX)
DBV Technologies S A 23306J309 (DBVT)
Trevi Therapeutics 89532M101 (TRVI)
Alumis 022307102 (ALMS)
Uniqure NV N90064101 (QURE)
Ultragenyx Pharmaceuticals 90400D108 (RARE)
Relay Therapeutics 75943R102 (RLAY)
Abivax SA 00370M103 (ABVX)
Dyne Therapeutics 26818M108 (DYN)

View all positions for MPM Oncology Impact Management

Top funds holding Taysha Gene Therapies

venBio Select Advisor
RA Capital Management
Goldman Sachs Group
BlackRock
Vestal Point Capital
Morgan Stanley
Rtw Investments
FMR
Vanguard Capital Management
State Street Corporation
Octagon Capital Advisors
Siren
Geode Capital Management
Polar Capital Holdings
MPM Oncology Impact Management

View all funds holding Taysha Gene Therapies